Literature DB >> 19137009

Activation of the non-canonical Dvl-Rac1-JNK pathway by Frizzled homologue 10 in human synovial sarcoma.

C Fukukawa1, S Nagayama, T Tsunoda, J Toguchida, Y Nakamura, T Katagiri.   

Abstract

We previously reported that Frizzled homologue 10 (FZD10), a member of the Wnt signal receptor family, was highly and specifically upregulated in synovial sarcoma and played critical roles in its cell survival and growth. We here report a possible molecular mechanism of the FZD10 signaling in synovial sarcoma cells. We found a significant enhancement of phosphorylation of the Dishevelled (Dvl)2/Dvl3 complex as well as activation of the Rac1-JNK cascade in synovial sarcoma cells in which FZD10 was overexpressed. Activation of the FZD10-Dvls-Rac1 pathway induced lamellipodia formation and enhanced anchorage-independent cell growth cells. FZD10 overexpression also caused the destruction of the actin cytoskeleton structure, probably through the downregulation of the RhoA activity. Our results have strongly implied that FZD10 transactivation causes the activation of the non-canonical Dvl-Rac1-JNK pathway and plays critical roles in the development/progression of synovial sarcomas.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19137009     DOI: 10.1038/onc.2008.467

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  32 in total

Review 1.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

Review 2.  Planar cell polarity (PCP) proteins and spermatogenesis.

Authors:  Haiqi Chen; C Yan Cheng
Journal:  Semin Cell Dev Biol       Date:  2016-04-19       Impact factor: 7.727

3.  Vascular smooth muscle LRP6 limits arteriosclerotic calcification in diabetic LDLR-/- mice by restraining noncanonical Wnt signals.

Authors:  Su-Li Cheng; Bindu Ramachandran; Abraham Behrmann; Jian-Su Shao; Megan Mead; Carolyn Smith; Karen Krchma; Yoanna Bello Arredondo; Attila Kovacs; Kapil Kapoor; Laurence M Brill; Ranjan Perera; Bart O Williams; Dwight A Towler
Journal:  Circ Res       Date:  2015-06-01       Impact factor: 17.367

4.  Wnt/β-catenin signaling directly regulates Foxj1 expression and ciliogenesis in zebrafish Kupffer's vesicle.

Authors:  Alissa Caron; Xiaolei Xu; Xueying Lin
Journal:  Development       Date:  2011-12-21       Impact factor: 6.868

5.  Tumor-initiating cells and FZD8 play a major role in drug resistance in triple-negative breast cancer.

Authors:  Shuping Yin; Liping Xu; R Daniel Bonfil; Sanjeev Banerjee; Fazlul H Sarkar; Seema Sethi; Kaladhar B Reddy
Journal:  Mol Cancer Ther       Date:  2013-02-27       Impact factor: 6.261

Review 6.  Hear the Wnt Ror: how melanoma cells adjust to changes in Wnt.

Authors:  Michael P O'Connell; Ashani T Weeraratna
Journal:  Pigment Cell Melanoma Res       Date:  2009-08-25       Impact factor: 4.693

Review 7.  Targeting the Wnt pathway in human cancers: therapeutic targeting with a focus on OMP-54F28.

Authors:  Phuong N Le; Jessica D McDermott; Antonio Jimeno
Journal:  Pharmacol Ther       Date:  2014-08-27       Impact factor: 12.310

Review 8.  Frizzled homolog proteins, microRNAs and Wnt signaling in cancer.

Authors:  Koji Ueno; Hiroshi Hirata; Yuji Hinoda; Rajvir Dahiya
Journal:  Int J Cancer       Date:  2012-08-30       Impact factor: 7.396

Review 9.  WNT/Frizzled signalling: receptor-ligand selectivity with focus on FZD-G protein signalling and its physiological relevance: IUPHAR Review 3.

Authors:  J P Dijksterhuis; J Petersen; G Schulte
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

10.  Wnt pathway reprogramming during human embryonal carcinoma differentiation and potential for therapeutic targeting.

Authors:  Grace E Snow; Allison C Kasper; Alexander M Busch; Elisabeth Schwarz; Katherine E Ewings; Thomas Bee; Michael J Spinella; Ethan Dmitrovsky; Sarah J Freemantle
Journal:  BMC Cancer       Date:  2009-10-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.